Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy

Fig. 2

Human PD1-Fc-OX40L ARC binds with high affinity to PD-L1, PD-L2, and OX40. On-rate (Ka), off-rate (Kd) and binding affinity (KD) were determined by surface plasmon resonance for PD1-Fc-OX40L binding to chip immobilized (a) PD-L1-His, (b) PD-L2-His, and (c) OX40-His. Recombinant human PD1-Fc and OX40L-Fc were used as controls for binding. (d) Summary of binding results depicted in the graphs (a-c)

Back to article page